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Abstract: Gastric cancer constitutes a signiﬁ  cant health problem in the world due to its high 
incidence in certain geographical areas. The basic treatment of this tumor in its localized stages 
is surgery. Unfortunately, survival is less than 5 years, despite radical surgery. Radical and 
extensive surgery has proved to be crucial to survival, although there is no agreement on the 
need for reaching the nodes until there is more than 3 cm of tumor. However, even with the 
most extensive surgery, survival does not reach more than approximately 35% at 5 years, if we 
consider all the localized stages. Adjuvant treatment is therefore necessary for this neoplasm. 
The role of post-operative chemotherapy, as that of radiochemotherapy, is not well established 
and there is no standard. However, there is relative evidence of the beneﬁ  t of adjuvant treatment 
in some chemotherapy studies and in combination with radiotherapy, so that it is an option for 
treatment in these patients. 
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Introduction
Gastric cancer constitutes an important social and health problem worldwide, due to 
its high incidence in particular geographical areas. In Europe it ranks ﬁ  fth after lung, 
prostate, colorectal and bladder cancer in men, and breast, colorectal, lung and uter-
ine cancer in women. On a global scale it represents 24% of all malignant neoplasia 
(Ferlay et al 2001). The survival at 5 years has increased slightly from 17% to 22%, 
with the stage being the determining prognostic factor. The rate is 2% at 5 years for 
disseminated neoplasia, and approximately 60% in more localized tumors. 
Surgery is still the treatment chosen for patients with localized gastric cancer, but 
adjuvant treatment is necessary as a result of these patients’ low overall survival, even 
after radical R0 D2 surgery. (In Table 1, the concepts of R and D used in this paper 
are deﬁ  ned.) The survival rate after curative resection is 30%–40%, with the stage 
and location of the tumor being the major inﬂ  uential factors. A proximal location has 
the worst prognosis, as can be seen in Table 2 (Meyerhardt and Fuchs 2003). In any 
case, it is remarkable that even for stage IA, more than 20% of patients are expected 
to relapse and die within 5 years. The failure of the treatment is produced by a com-
bination of local relapses and distance dissemination, with local relapse showing a 
very signiﬁ  cant percentage. The distribution of relapses is summarized in Table 3, 
and includes the analysis of four recent series. Loco-regional relapses reach between 
30%–50% as a whole, with distance dissemination between 18%–54% according to 
the series. This high percentage of local relapses favors the inclusion of radiotherapy 
in the adjuvant treatment of this tumor.
Extent of surgery and adjuvant chemotherapy
The efﬁ  cacy of the extent of surgery is a controversial aspect with great importance 
in the indication of adjuvant treatment. Two large studies have been published on this Therapeutics and Clinical Risk Management 2007:3(4) 564
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aspect. The study by the German group (German Gastric 
Cancer Study group) Roder et al 1993 (record study) showed 
that patients in stages II and IIIA who had undergone R0 
and D2 surgery (>25 nodes resected) gained signiﬁ  cant im-
provement in survival compared with those patients who had 
undergone standard resection. The Dutch study (Bonenkamp 
et al 1999) (randomized study) and the Cuschieri study (Cus-
chieri et al 1999) reached the opposite conclusion – that D2 
surgery should not be considered as the standard treatment. 
In this study, the extent of the surgery (D1 vs. D2) entailed 
better staging of patients, without showing improvement in 
survival for the stages. However, it is difﬁ  cult to ignore that 
in the German study, the survival at 5 years increased from 
26% to 55% in stage II for D2 surgery. 
In this context, the role of adjuvant chemotherapy has 
not been deﬁ  ned. There are other relatively recent studies 
with signiﬁ  cant results, although the majority of these could 
not be reproduced, or lack statistical power due to the small 
number of cases (Table 4).
The studies by Cirera et al (1999) and Neri et al (2001) 
are worth a separate mention. In the study by Neri et al the 
treatment used was epirubicin, 5-ﬂ  uorouracil (5-FU) and 
leucovorin (LV). We can include this as a more common 
treatment than those used in most studies that make up the 
meta-analyses published until now. All patients had positive 
nodes; 88% of patients received the scheduled treatment. 
The average survival for the group treated was 31 months, 
almost double that of the control group, which had an aver-
age survival of 18 months (p < 0.01). The survival at 5 years 
was 30% of treated patients in contrast with 13% of the 
control group. Although there was toxicity grade 3–4, with 
12% of patients having mucositis, 8.7% diarrhoea and 7% 
leukopenia, the level of toxicity was acceptable and there 
were no cases of hospitalization. The study by Cirera et al 
involved 156 patients, all in stage III including cases of N0. 
In this study, the treatment was very simple and included 
a single dose of mitomycin (MMC) followed by 3 months 
of oral tegafur daily. It is important to highlight that all the 
patients included had undergone R0 D2 surgery. The results 
were highly signiﬁ  cant, with 56% survival at 5 years for 
the treated group and 31% for the control group (p = 0.04). 
In this case, the price of obtaining the survival beneﬁ  t was 
minimal, with only one case of grade 3 toxicity. Although 
conﬁ  rmation studies with a greater number of cases are 
necessary, these data should not be ignored. In the study by 
Cirera et al the greatest percentage of relapses were local and 
peritoneal, reaching 33% in the non-treated group. Although 
no signiﬁ  cant results were reached, the study developed by 
ITMO group (Italian Trials in Medical Oncology) is very 
interesting. There were 274 patients included in it with T3, 
T4 or N1, N2. Chemotherapy consisted of two cycles of EAP 
(etoposide, adriamycin, and cisplatin) followed by two cycles 
of 5FULV according to Machover’s scheme with leucovorin. 
Survival at 5 years was 48% for the control group and 52% 
for the treatment group without signiﬁ  cant statistical differ-
ence. The highest beneﬁ  t was for patients N+ with more than 
6 nodules whose survival was 22% and 42% respectively. 
The authors also point out the importance of the D2 surgery 
performed in the study, inﬂ  uencing the high survival achieved 
in both groups (Bajetta et al 2002). 
Some molecular alterations have been described in 
gastric cancer as indicative factors of different biological 
behavior and prognosis which may relate to the different 
results achieved. We quote as an example the microsatellite 
instability, present in 13%–44% of sporadic gastric cancers 
which confers better prognosis (dos Santos et al 1996) or 
some speciﬁ  c somatic changes that can occur in p53 without 
a clear prognosis or in p16INK4 related to gastroesophageal 
junction cancers (Wong et al 1997). The anatomical location 
Table 1 Deﬁ  nition of “R” and “D”. R refers to the type of resection 
carried out. D refers to the extent of the lymph node dissection
R0  Curative resection without residual disease
R1  Resection with curative intention but with microscopic residual
 disease
R2  Palliative resection with macroscopic residual disease
D1  Resection of tumor and adjacent nodes only
D2  Resection including coeliac and perigastric nodes up to >3 cm
  of the primary T
Table 3  Distribution of gastric cancer relapses
Local Peritoneal  Distant Ref.
23%  54%  54%  Schwarz et al 2002 
42%–48%  21%–52%  25%–46%  Marrelli et al 2002 
29%  72%  18%  Macdonald et al 2001 
38%–93%  30%–43%  49%  Gunderson et al 2002 
Table 2  Survival at 5 years by stage and location of tumor
Stage Overall  Antrum/pylorus  Cardia/fundus
IA 78%  81%  64%
IB 58%  65%  42%
II 34% 38%  24%
IIIA 20%  23%  13%
IIIB 8%  6%  6%
IV 7%  9%  6%Therapeutics and Clinical Risk Management 2007:3(4) 565
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has also been described as a prognostic factor. In this sense 
the work by the ITMO group included this parameter in the 
multivaried analisis (Cox model) proving to be an independ-
ent prognostic factor, being the location in middle and distal 
third better prognosis than in the upper third (p:0.033). 
Five meta-analyses have been published. The ﬁ  rst, by 
Hermans et al (1993), reviewed 11 trials (2000 patients) that 
compared adjuvant treatments with very uneven therapies, 
including intraperitoneal chemotherapy, radiotherapy and 
chemotherapy combined with immunotherapy, with surgery 
as a control arm. They did not show any survival beneﬁ  t in 
the combined arm. The second meta-analysis was presented 
by Earle and Maroun (1999). They compiled 13 clinical trials, 
including 1990 patients, and found a small but signiﬁ  cant 
survival beneﬁ  t for patients treated with chemotherapy (odds 
ratio 0.80, relative risk 0.94). Mari et al (2000) analyzed 
more than 20 articles taking into account more than 300 
patients, and showed an 18% reduction in the risk of death 
(HR 0.82, p < 0.001). Panzini et al (2002) evaluated more 
than 3000 patients in a total of 17 clinical trials. Their results 
showed signiﬁ  cant survival beneﬁ  t in patients treated with 
adjuvant chemotherapy (odds ratio 0.72). Finally Hu et al 
(2002) reviewed 14 trials involving more than 4500 patients. 
They found survival beneﬁ  t in patients treated adjuvantly 
(odds ratio 0.56). In short, 4 meta-analyses suggest survival 
beneﬁ  t, being the most favorable group being that presenting 
nodular affectation. 
Another approach to adjuvant treatment of gastric cancer 
is the perioperative chemotherapy used in the MAGIC trial 
(Cunningham et al 2006). The study included 503 patients 
with gastric or esophagogastric junction adenocarcinoma 
in stage II or higher, randomized in to control or to receive 
three pre-operative cycles and three post-operative cycles 
of chemotherapy with ECF (epirubicine, cisplatin, and 
infusional 5FU). The extension of surgery (D1,D2) follows 
the surgeon’s criteria. Survival at 5 years, although lower 
than in other studies, shows signiﬁ  cant difference (p:0.009) 
favoring the treatment group with 36% in comparison with 
the 23% of the control group. A fact of great interest in this 
study is that in the pre-treated group the average of tumor 
size, the T and the N are signiﬁ  cantly smaller showing the 
beneﬁ  t of pre-operative treatment.
Considering this evidence and the lack of a standard, we 
should consider whether the patient, ie, the ordinary patient 
outside a clinical trial, should be advised to undergo com-
plementary treatment after apparently radical surgery (R0, 
D1–D2). If the answer is yes, what is the most suitable treat-
ment? Is chemotherapy enough? Should we always advise 
radiochemotherapy?
Local relapse and radiotherapy
We have already mentioned the importance of local relapse 
in this neoplasm. This has motivated the inclusion of 
radiotherapy in the adjuvant treatment of this tumor, in spite 
of the technical and practical difﬁ  culties that it entails. The 
most relevant radiochemotherapy studies are summarised in 
Table 5. Two of these are not comparative, which limits their 
value (Park et al 2003; Lim et al 2004). In both, D2 surgery 
was performed and the patients were treated with 5FU/LV + 
RT (radiotherapy); they reached a survival of 58% and 60% 
Table 4  Adjuvant chemotherapy studies with positive results
Study  Treatment  No.   Sup   p  Criticism
   p  %   
GITSG 1982  MeCCNU + 5FU  71    <0.03  Not reproduced in 
  Control  71      VASOG y ECOG
Neri et al 2001  Epi + 5FU/LV  69  30  <0.01  ?
   Control  68  13   
Grau et al 1998  MMC  45  44  0.004  Small number of cases.
  MMC + tegafur  40  67    11 years conscription.
          No control group
Hagiwara  IP carbon-absorbed   24  69    Small number of cases.
et al 1992  cisplatin      <0.005  Australian study 
 Control  25  27    negative.
Kim et al 1992  MMC + 5FU + AraC + OK432  74  45  <0.05  Small number of cases. 
 Control  64  23    Not  reproduced
Cirera et al 1999  MMC + tegafur  76  56  0.04  ?
 Control  72  36
Abbreviations: FU, ﬂ  uorouracil; LT, leucovorin; MMC, mitomycin.Therapeutics and Clinical Risk Management 2007:3(4) 566
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at 5 years. It is worth highlighting that this survival is not 
different from that reached in some adjuvant chemotherapy 
studies, such as that by Cirera et al in which there was 56% 
survival in the treated group at 5 years. The study by Mac-
donald et al (2001) (INT-0116) compared one treatment arm 
(5FU/LV + RT) with a group of surgery only. The results of 
survival and the disease-free interval (DFI) at 3 and 5 years 
show signiﬁ  cant improvement in favor of the treatment group, 
with a survival of 50% and 40%. (Although the results at 5 
years have not been published, they show an 11.6% increase 
in survival beneﬁ  t, 40% vs 28.4% (p  <  0.001), and survival 
free of relapse increased from 25% to 31% (p  <  0.001) in the 
radiochemotherapy arm). These were lower than the results 
found by Hagiwara et al (1992) and Cirera et al (1999) with 
chemotherapy alone, comparing 41% and 28.4% in the control 
group (p < 0.005) and with DFI of 48% and 31% as against 
31% and 25% (p < 0.005) The results of this study have led 
to post-operative radiochemotherapy being considered by 
many as standard in the treatment of gastric cancer, in spite 
of the fact that it is widely considered reprehensible. The most 
signiﬁ  cant criticism (see Table 4) is convincing. Compliance 
with the protocol was under 64%, and 26% were abandoned 
due to toxicity or patient rejection. Due to the complexity 
of the radiotherapy protocol, in 35% of cases the treatment 
schedule had to be corrected. The most important criticism 
was that the surgery was very low quality, with only 10% D2 
surgery and 36% D1, ie, more than half the patients received 
non-curative surgery with D0 resections, a fact that the 
authors defend as the reality of gastric surgery in the USA. 
Survival at 3 years for the patients who had undergone D1 
or D2 resection in the Dutch study reached 60%, 20% more 
than in Macdonald’s study, by which we can conclude that 
poor surgery was a poor prognostic factor in the INT-0116 
study. What would the results of this study have been with 
R0 D2 surgery in all patients?
Another aspect for discussion is the real effect of radio-
therapy on local relapses. Table 6 shows the percentages of 
locoregional relapse in studies with surgery alone, chemo-
therapy alone and radiochemotherapy. We can see that the 
rates of local relapse are similar in any of these situations. 
Table 5  Studies of adjuvant radiochemotherapy
Study Treatment  P  Sup  %  p  Criticism
Lim et al 2004  5FU/LV + RT  291  58  -  Not comparative
 D2  Surgery       
Park et al 2003  5FU/LV + RT  261  60  -  Not comparative
 D2  Surgery       
Macdonald et al   5FU/LV + RT  281  50%*    Low compliance with protocol 
2001 Control    41%*    (64%)
INT-0116  D2 Surgery         17% abandoned due to toxicity
  10%    *3    35% revision of RT plan
  D1 Surgery    years    3 toxic deaths
 36%        Poor quality of surgery
Abbreviations: FU, ﬂ  uorouracil; LT, leucovorin; RT, radiotherapy.
Table 6 Locoregional relapses according to treatment
Study P  Treatment  Locoregional    Relapse*  p*
 No.  rel/(Total  no.)    relapses  predictors 
Schwarz et al   35/(73)  Surgery R0D2  23%  N3  0.005
2002      only local 6%  T3/T4  0.008
Cirera et al   37/(76)  Surgery D2 + CT  26%  –  –
1999 50/(72)  Surgery  D2  33%   
Lim et al   114/(291)  Surgery   19%  N3  <0.0001
2004    D2 + CT + RT  only local 7%  T3/T4  <0.0001
Park et al   114/(261)  Surgery   29%  III/IV (M0)  <0.001
2003    D2 + CT + RT     
Macdonald    120(281)  10% D2 Surgery  19%   
et al 2001     + CT + RT    –  **NS
(INT-0116)   177/(275)  10% D2 Surgery  29%**   
Abbreviations: CT, chemotherapy; RT, radiotherapy.Therapeutics and Clinical Risk Management 2007:3(4) 567
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Two facts are worth mentioning: one, that solely local 
relapses are scarce in the studies that have been carried out, 
and secondly, that they do not differentiate between R0 D2 
surgery alone and those with adjuvant radiochemotherapy 
treatment. On the other hand, in the INT-0116 study there is 
no signiﬁ  cant difference in locoregional relapses according 
to the arm of treatment.
Final comments
Therefore, in general, there are positive data to advise the 
use of adjuvant treatment in gastric cancer in N3 and T3/T4. 
There is no evidence that radiotherapy improves the rate of 
locoregional relapses in patients who undergo R0 D2 surgery. 
Even in Macdonald’s study, there is no signiﬁ  cant difference 
between the two arms, despite D0 surgery in 53% of cases. 
The optimum treatment has not been established, but as 
there is probably real potential beneﬁ  t, it seems reasonable 
to opt for any of the treatments that have shown positive 
results, bearing in mind the patient’s circumstances and 
the infrastructures available. For incomplete surgery (R1, 
R2 or D0), it seems advisable to include radiotherapy in 
the complementary treatment. In any case, a discussion of 
the pros and cons with the patient is fundamental to reach 
what should be a joint decision. However the development 
of new trials that allow a deﬁ  nitive standard treatment to be 
established is necessary.
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